The search terms included "CGRP antibodies," "migraine prevention," "erenumab," "fremanezumab," "galcanezumab," and "eptinezumab." The inclusion criteria included articles published between 2018 and 2023 and directly related to the treatment and prevention of migraine. This evidence concerns the gene CALCA and migraine disorder.